Compare ETR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETR | EW |
|---|---|---|
| Founded | 1949 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Industrial Specialties |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9B | 49.9B |
| IPO Year | 2005 | 1999 |
| Metric | ETR | EW |
|---|---|---|
| Price | $114.20 | $87.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 21 |
| Target Price | ★ $115.25 | $96.37 |
| AVG Volume (30 Days) | 2.7M | ★ 3.9M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 59.59 | N/A |
| EPS | ★ 0.83 | 0.66 |
| Revenue | ★ $12,946,686,000.00 | $6,067,600,000.00 |
| Revenue This Year | $8.40 | $13.39 |
| Revenue Next Year | $8.09 | $9.81 |
| P/E Ratio | $138.92 | ★ $136.27 |
| Revenue Growth | 8.98 | ★ 11.55 |
| 52 Week Low | $83.14 | $72.30 |
| 52 Week High | $118.45 | $96.29 |
| Indicator | ETR | EW |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 43.49 |
| Support Level | $112.12 | $82.02 |
| Resistance Level | $117.73 | $89.48 |
| Average True Range (ATR) | 1.95 | 2.29 |
| MACD | -0.05 | -0.58 |
| Stochastic Oscillator | 43.14 | 5.64 |
Entergy is a holding company with five regulated vertically integrated utilities that generate and distribute electricity to 3 million customers in Arkansas, Louisiana, Mississippi, and Texas. It is one of the largest power producers in the country with 27 gigawatts of rate-regulated owned and leased power generation capacity. Entergy was the second-largest nuclear owner in the US before it began retiring and selling its plants in the Northeast in 2014. It sold its two small gas utilities in Louisiana in 2025.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.